Galapagos initiates Phase 1 trial for second Toledo compound - GlobeNewswire

Galapagos initiates Phase 1 trial for second Toledo compound  GlobeNewswire

Mechelen, Belgium; 24 September 2019, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) started a Phase 1 trial with GLPG3970, a second generation ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases